Cubist Systematic Strategies LLC Acquires 126,161 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Cubist Systematic Strategies LLC grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 944.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,522 shares of the specialty pharmaceutical company's stock after purchasing an additional 126,161 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.25% of Supernus Pharmaceuticals worth $5,045,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of SUPN. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth $52,000. Headlands Technologies LLC lifted its holdings in shares of Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth $72,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth $92,000.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Trading Up 0.4%

Shares of SUPN stock traded up $0.13 during mid-day trading on Tuesday, reaching $32.28. The stock had a trading volume of 379,967 shares, compared to its average volume of 493,408. The stock's 50-day moving average price is $31.86 and its two-hundred day moving average price is $34.89. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The firm has a market capitalization of $1.81 billion, a PE ratio of 30.17 and a beta of 0.74.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. StockNews.com downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.